PMID- 32815051
OWN - NLM
STAT- MEDLINE
DCOM- 20210412
LR  - 20211204
IS  - 1875-8312 (Electronic)
IS  - 1569-5794 (Linking)
VI  - 37
IP  - 1
DP  - 2021 Jan
TI  - Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial 
      stiffness in heart failure with reduced ejection fraction.
PG  - 165-173
LID - 10.1007/s10554-020-01973-8 [doi]
AB  - The sacubitril/valsartan combination is an important agent used in the treatment 
      of heart failure with reduced ejection fraction (HFrEF). Pulmonary artery 
      stiffness (PAS) is an index developed to evaluate the pulmonary vascular bed. 
      Changes in pulmonary vascular structures in HFrEF patients can affect PAS. In 
      this study, we aimed to investigate the effect of sacubitril/valsartan on PAS in 
      HFrEF patients. One hundred fifty HFrEF patients, who received 
      sacubitril/valsartan therapy and continued for at least 6 months without 
      interruption, were examined retrospectively. N-terminal pro-B-type natriuretic 
      peptide levels (NT-proBNP), NYHA classes, Minnesota Living with Heart Failure 
      Questionnaire (MLWHFQ) scores, New York Heart Association (NYHA) functional 
      classes and echocardiograpic parameters such as left ventricular ejection 
      fraction (LVEF), mean pulmonary artery pressure (mPAP), right ventricle 
      myocardial performance index (RV-MPI), Tricuspid annular plane systolic excursion 
      (TAPSE), right ventricular fractional area change (RV-FAC) and PAS changes were 
      evaluated before and 6 months after sacubitril/valsartan treatment. PAS was 
      calculated by using the maximal frequency shift and acceleration time of the 
      pulmonary artery flow trace measured in the echocardiogram. PAS values were 
      significantly reduced (23.8 +/- 2.8 vs 19.1 +/- 3.1 kHz/ms, p < 0.001) after the 
      sacubitril/valsartan treatment. Sacubitril/valsartan treatment was associated 
      with significant improvements in NYHA class and MLWHFQ scores; significant 
      reductions in the NT-proBNP levels, mPAP, and RV-MPI, and significant increases 
      in LVEF, TAPSE, and RV-FAC (p < 0.05). The significant reduction in the PAS value 
      was significantly correlated with the improvements in the MLWFQ scores, NT-proBNP 
      levels, mPAP, RV-MPI, TAPSE and RV-FAC. In HFrEF patients, switching from 
      angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy 
      to sacubitril/valsartan may result in reduction in PAS.
FAU - Yenercag, Mustafa
AU  - Yenercag M
AD  - Department of Cardiology, University of Health Sciences Samsun Training and 
      Research Hospital, Baris Bulvari, No: 199, 55400, Samsun, Turkey.
FAU - Arslan, Ugur
AU  - Arslan U
AUID- ORCID: 0000-0001-8572-3571
AD  - Department of Cardiology, University of Health Sciences Samsun Training and 
      Research Hospital, Baris Bulvari, No: 199, 55400, Samsun, Turkey. 
      ugurarslan5@yahoo.com.
FAU - Dereli, Seckin
AU  - Dereli S
AD  - Deparment of Cardiology, Ordu University Faculty of Medicine, Ordu, Turkey.
FAU - Coksevim, Metin
AU  - Coksevim M
AD  - Deparment of Cardiology, Ondokuz Mayis University Faculty of Medicine, Samsun, 
      Turkey.
FAU - Dogdus, Mustafa
AU  - Dogdus M
AD  - Department of Cardiology, University of Usak Training and Research Hospital, 
      Usak, Turkey.
FAU - Kaya, Ahmet
AU  - Kaya A
AD  - Deparment of Cardiology, Ordu University Faculty of Medicine, Ordu, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20200819
PL  - United States
TA  - Int J Cardiovasc Imaging
JT  - The international journal of cardiovascular imaging
JID - 100969716
RN  - 0 (Aminobutyrates)
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Drug Combinations)
RN  - 0 (Protease Inhibitors)
RN  - 0 (Tetrazoles)
RN  - 80M03YXJ7I (Valsartan)
RN  - EC 3.4.24.11 (Neprilysin)
RN  - WB8FT61183 (sacubitril and valsartan sodium hydrate drug combination)
SB  - IM
MH  - Aged
MH  - Aminobutyrates/adverse effects/*therapeutic use
MH  - Angiotensin II Type 1 Receptor Blockers/adverse effects/*therapeutic use
MH  - Biphenyl Compounds
MH  - Cross-Sectional Studies
MH  - Drug Combinations
MH  - Echocardiography, Doppler, Pulsed
MH  - Female
MH  - Heart Failure/diagnostic imaging/*drug therapy/physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neprilysin/*antagonists & inhibitors
MH  - Protease Inhibitors/adverse effects/*therapeutic use
MH  - Pulmonary Artery/diagnostic imaging/*drug effects/physiopathology
MH  - Retrospective Studies
MH  - Stroke Volume/*drug effects
MH  - Tetrazoles/adverse effects/*therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
MH  - Valsartan
MH  - Vascular Stiffness/*drug effects
MH  - Ventricular Function, Left/*drug effects
OTO - NOTNLM
OT  - Heart failure
OT  - Pulmonary artery stiffness
OT  - Sacubitril/valsartan
EDAT- 2020/08/21 06:00
MHDA- 2021/04/13 06:00
CRDT- 2020/08/21 06:00
PHST- 2020/07/14 00:00 [received]
PHST- 2020/08/14 00:00 [accepted]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/04/13 06:00 [medline]
PHST- 2020/08/21 06:00 [entrez]
AID - 10.1007/s10554-020-01973-8 [pii]
AID - 10.1007/s10554-020-01973-8 [doi]
PST - ppublish
SO  - Int J Cardiovasc Imaging. 2021 Jan;37(1):165-173. doi: 
      10.1007/s10554-020-01973-8. Epub 2020 Aug 19.